Proactive Investors - Run By Investors For Investors

Scancell-led team short-listed for award

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding
woman at microscope
The scientists are aiming to identify the most effective treatments for patients with most strains of the disease

A team led by Scancell Holdings Plc’s (LON:SCLP) chief scientific officer that is pioneering a vaccine-led approach to tackling tumours has been shortlisted for  a £20mln award.

Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.

The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.

However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.

Modi-3 may play a role

As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.

Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.

Last year four teams won financial backing from the charity.

READ: Scancell eyeing investigational new drug application for SCIB1 in first half

Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint. 

“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. 

“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use